NICE Overcomes UK Reimbursement Doubts Over Forxiga, US FDA Says No To Approval
Executive SummaryThe health technology appraisal body for England and Wales now says Forxiga can help fill an unmet need for patients with inadequately controlled type 1 diabetes despite optimized insulin therapy. US regulators, meanwhile, have declined to approve the product for use in these patients.
You may also be interested in...
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.
The EU marketing application for cefiderocol that lost fast track status last July is now up for an opinion by the European Medicines Agency.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.